Every material Form 8-K Zentalis Pharmaceuticals, Inc. has filed with the SEC since May 27, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Zentalis Pharmaceuticals entered an underwriting agreement on August 13, 2026 to sell 23,000,000 new common shares at $3.50 per share, before underwriting discounts. The company estimates net proceeds of about $75.1 million, which it plans to use for clinical trials, regulatory filings, manufacturing, pre-commercial activities and general corporate purposes. Shareholders face dilution from the new shares, and the underwriters also hold a 30-day option to buy up to 3,450,000 more shares.
23,000,000 shares offered at $3.50 per share, less underwriting discounts and commissions
Estimated net proceeds of approximately $75.1 million after discounts and offering expenses
Underwriters have a 30-day option to buy up to 3,450,000 additional shares
Closing expected on August 17, 2026, subject to customary conditions
Zentalis reported a second-quarter 2026 net loss of $42.3 million, or $0.59 per share, up from $26.9 million, or $0.37 per share, a year earlier, as operating expenses rose to $44.4 million. Cash, cash equivalents and marketable securities declined to $174.6 million from $245.9 million at December 31, 2025, and the company says that balance funds operations into late 2027, which matters to shareholders because the company has no approved product and depends on the azenosertib program.
Net loss of $42.3 million ($0.59 per share) for the quarter ended June 30, 2026, versus $26.9 million ($0.37 per share) for the same quarter of 2025
R&D expenses of $35.2 million, up from $27.6 million, including a $7.0 million milestone payment to Recurium IP Holdings, LLC tied to the start of the Phase 3 ASPENOVA trial
Cash and marketable securities of $174.6 million at June 30, 2026, down from $245.9 million at December 31, 2025; runway stated into late 2027
Zentalis Pharmaceuticals increased its Board from six to seven directors and appointed Shannon Campbell as a Class I director effective May 22, 2026. She also joined the Compensation Committee and receives standard non-employee director pay and equity grants.
Board size increased from six to seven directors, effective May 22, 2026.
Campbell's initial term runs to the 2027 Annual Meeting of Stockholders.
Annual retainer of $45,000 for Board service, plus $7,500 for Compensation Committee membership.
Initial RSU grant of 114,200 shares on May 26, 2026, vesting in thirds over three years.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Zentalis Pharmaceuticals, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →